MARKET

GYRE

GYRE

Gyre Therapeutics Inc
NASDAQ
7.69
+0.30
+4.06%
After Hours: 7.60 -0.09 -1.17% 17:12 04/13 EDT
OPEN
7.37
PREV CLOSE
7.39
HIGH
7.72
LOW
7.31
VOLUME
49.90K
TURNOVER
--
52 WEEK HIGH
11.78
52 WEEK LOW
6.57
MARKET CAP
745.65M
P/E (TTM)
157.91
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GYRE last week (0406-0410)?
Weekly Report · 22h ago
Weekly Report: what happened at GYRE last week (0330-0403)?
Weekly Report · 04/06 09:10
Weekly Report: what happened at GYRE last week (0323-0327)?
Weekly Report · 03/30 09:10
Gyre Therapeutics Files NDA in China for F351
TipRanks · 03/23 12:23
Gyre Therapeutics submits Hydronidone NDA to China NMPA for CHB-induced liver fibrosis
Reuters · 03/23 11:51
Weekly Report: what happened at GYRE last week (0316-0320)?
Weekly Report · 03/23 09:10
Buy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval
TipRanks · 03/17 14:15
Gyre Therapeutics’ liver fibrosis candidate granted priority review in China
TipRanks · 03/17 11:20
More
About GYRE
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.

Webull offers Gyre Therapeutics Inc stock information, including NASDAQ: GYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GYRE stock methods without spending real money on the virtual paper trading platform.